Moderna Shares Are Trading Lower. The Company Earlier Announced Phase 3 MRNA-1083 Trial Data, Which Met Its Primary Endpoint.
Moderna Shares Are Trading Lower. The Company Earlier Announced Phase 3 MRNA-1083 Trial Data, Which Met Its Primary Endpoint.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.